On the first anniversary of Stephen Harrison’s passing, we take an episode to remember our co-founder and colleague, Stephen Harrison, his contributions to MASH and how his legacy moves forward.
SurfingMASH kicks off a month of Drug Development stories looking at FGF-21s and the future of therapies for cirrhosis and MASH, plus a paper on real-world resmetirom prescribing.
This week’s Newsmaker is Mike Betel, Founder of the Fatty Liver Alliance. He discusses some of the reasons that key MASLD Patient Advocates like himself are getting more visibility at a broader swath of global conferences and the messages he delivers at the conferences he attends.
This conversation starts by asking whether approval of two drugs for use without biopsy will challenge MASH trial recruitment and goes on to look at recent studies discussing patient genotyping and clustering.
Global Liver Institute Vice President of Liver Programs Jeff McIntyre joins Roger Green to discuss what he considers key takeaways for GLI from EASL Congress 2024.
PharmaNest Founder and CEO Mathieu Petitjean and Global LIver Institute Vice President of Liver Programs Jeff McIntyre join Roger Green for 1:1 interviews exploring their key takeaways and strategic shifts resulting from the EASL Congress 2024, followed by a review of answers to a previous Question of the Week.
Roger Green speaks with SurfingMASH co-host and Tawazun Health Founder and Clinical Director Louise Campbell on the last day of the EASL Congress. Their conversation focuses on how practice patterns, guidelines and training might change over the next few years.
Roger Green speaks with SurfingMASH co-host and Tawazun Health Founder and Clinical Director Louise Campbell on the last day of the EASL Congress. The discussion covers Clinical Practice Guidelines, drug development and NITs.
For most of this conversation, updated MASLD CPG co-authors Frank Tacke and Elisabetta Bugianesi discuss key issues related to pharmacology and prescribing choices. At the end, the focus shifts to the guidelines’ overall benefits and some new kinds of education they call for.
In this conversation, updated MASLD CPG co-authors Frank Tacke and Elisabetta Bugianesi discuss some of the guidelines’ key goals and issues surrounding the screening, diagnosis and management of MASLD patients.
